Fig 1.
Filtering procedure for MS and SLE cohorts.
Table 1.
Population characteristics.
Table 2.
ICD-9 /10 and lab codes.
Table 3.
Logistic regression models.
Fig 2.
Autoimmune disorders increase viral incidence.
Viral incidence increases overall cancer risk within the autoimmune cohorts. Odds ratios (OR) and 95% confidence intervals of SLE and MS cohorts. For all graphs, the dotted line represents an OR of 1.0. An OR to the right of the dotted line represents an increase in risk. An OR to the left of the solid line represents a reduction in risk. (a) Overall viral incidence is significantly predicted by SLE (OR 1.60, 95% CI 1.37, 1.87, p = 1.58x10-6) and being male with SLE (OR 1.58, 95% CI 1.27, 1.95, p = 2.16x10-4). (b) MS predicts increased positive viral status (OR 3.31, 95% CI 2.44, 4.56, p = 2.15x10-13). (c) Overall cancer incidence within the SLE cohort is significantly predicted by the viral status (OR 1.76, 95% CI 1.33, 2.31, p = 4.12x10-4) and being male (OR 1.65, 95% CI 1.33, 2.03, p = 2.72x10-5). (d) Overall cancer incidence within the MS cohort is significantly predicted by viral status (OR 4.65, 95% CI 1.74, 10.41, p = 0.0025).
Fig 3.
Autoimmune disorders increases risk of EBV infection, and autoimmune disorder with EBV increases risk for hematological cancers.
Odds ratios (OR) and 95% confidence intervals of SLE and MS cohorts are shown. For all graphs, the dotted line represents an OR of 1.0. An OR to the right of the dotted line represents an increase in risk. An OR to the left of the solid line represents a reduction in risk. (a) EBV viral incidence for SLE cohort is significantly predicted by SLE (OR 2.27, 95% CI 1.83, 2.81, p = 6.99 x 10−13). (b) EBV incidence for MS cohort is significantly predicted by MS (OR 3.99, 95% CI 2.72, 6.00, p = 2.49x10-11). (c) Hematological cancer incidence for the SLE cohort is significantly predicted by the interaction of SLE with EBV (OR 1.92, 95% CI 1.53, 2.41, p = 1.28x10-7) and male (OR 3.69, 95% CI 2.23, 5.84, p = 7.56x10-7). (d) Hematological cancer incidence for the MS cohort is predicted by interaction of MS with EBV (OR 1.83, 95% CI 1.34, 2.52, p = 7.85x10-4) and male (OR 17.12, 95% CI 4.90, 46.20, p = 1.43x10-6).
Fig 4.
SLE decreases risk for hormonal cancers.
Odds ratios (OR) and 95% confidence intervals of SLE and MS cohorts. For all graphs, the dotted line represents an OR of 1.0. An OR to the right of the dotted line represents an increase in risk. An OR to the left of the solid line represents a reduction in risk. (a) Breast cancer incidence in female SLE cohort is significantly decreased by SLE status (OR 0.52, 95% CI 0.35, 0.74, p = 0.0036). (b) Prostate cancer incidence in male SLE cohort is significantly decreased by SLE status (OR 0.23, 95% CI 0.089, 0.50, p = 0.0053).